Nordic American Tankers aka ticker NAT is now trading at $5.25 per share and this comes afters its highs of $9 a share. So why did stock NAT push up to $9 originally and why is it now crashing? So is stock NAT a buy or sell? Let's talk about it!
1.✅Free Investing Group: http://bit.ly/techbudsfbgroup
2. 📈A-Z Beginner Day Trading Course: https://learnplanprofit.net/
3. 👕New Apparel Line: https://shoptechbuds.com/
4. 🚗Join Car Investing Team: http://bit.ly/GETSTARTEDFLIPPING
● FOLLOW ME ON INSTAGRAM!
📸 Ricky's Insta: https://www.instagram.com/rickygutierrezz/
📸 Techbuds Insta: https://www.instagram.com/techbudsolutions/
For those who are interested in Trading & Investing, I encourage you to join Our Free Trading Group of over 250,000!
Thank you for the support, the best way to reach out to me is through our private discord chat, please DM me.
The Stock Market falling/ crashing can be a scary thing when you are not informed on how to make money during a stock market crash! The corona virus isn't getting any better and opportunity is among us, let's take time to inform ourselves and make the most of this opportunity!
If you have any suggestions for future videos such as Day Trading, Investing, Stock Market, Real Estate, Car Sales, Robinhood, TD Ameritrade, Crypto & bitcoin, Entrepreneurship, Forex, Online Marketing, Online Sales or fun daily vlogs. Please let me know.
DISCLAIMER: Please note that i do not ask for any information. I always encourage our members to trade ONLY what you understand and never based on anyone's opinion. My videos are for entertainment purposes only.any questions to message me as i would love to be a part of your success.
✅Surprise You Found $40 Off The LPP Course: http://bit.ly/40offLPP

By Stock Chat

where the coffee is hot and so is the chat

34 thoughts on “This is why nat nordic american tankers stock is crashing! down 40%”
  1. Avataaar/Circle Created with python_avatars thomas tolster says:

    People need to stop saying this as a reason for why stock is going down. Because that is what is driving it down! When it is based on much more than oil price!

  2. Avataaar/Circle Created with python_avatars scott stewart says:

    In my 5 years of long term investing, I have never been more confident in a stock tripling before year end with the lowest risk. Oil tanker stocks are it. I played the bitcoin wave, I played the MJ wave, this is a no brainer imo. Unless the market doesn't follow fundamentals anymore… You're a day trader totally different mindset and game. I could care less about what happens in 1 month.

  3. Avataaar/Circle Created with python_avatars Luis Serpa says:

    what you think about NASDAQ 100 (^NDX)? its being climbing day after day, shoud we espect to bet the max of 2 feb 2020?
    Thks in advance

  4. Avataaar/Circle Created with python_avatars Sharma Muthu says:

    LOL you have a bunch of stupid members. These kids shouldn't be trading please guide them before they make these trendy trades instead of making videos after the damage. They pay you for a reason

  5. Avataaar/Circle Created with python_avatars Xavier Mann says:

    Can u you do a vid about KC ?

  6. Avataaar/Circle Created with python_avatars bellm32 says:

    I’ve been preaching Uber I chose well there

  7. Avataaar/Circle Created with python_avatars Sussy Beans says:

    Every NAT video I see says pretty much the same thing, but NAT also transport oil right? If demand goes up, transportation of all the oil piled up should push the stock up imo. And if it goes down, then more storage demand, I pretty much see NAT going up any way oil goes. To me NAT is short to mid term hold. But the numbers and red does hurt 😂

  8. Avataaar/Circle Created with python_avatars Scott Duffy @ GetCloudSkills says:

    I don't agree. The price of oil isn't going to affect the price of NAT. It's the storage situation.

  9. Avataaar/Circle Created with python_avatars Mike-Oxhard says:

    Waiting til May 12 for earnings

  10. Avataaar/Circle Created with python_avatars SoloAdventures says:

    I’m staying in because the company is strong and maintains solid dividends.

  11. Avataaar/Circle Created with python_avatars Wholesome Stories says:

    Hi, can you suggest best platform for beginner with 2000$

  12. Avataaar/Circle Created with python_avatars Ely Pelowski says:

    I am still short term bullish. NAT is smart .. they required 6 month contracts to take on oil storage at $70k per day per ship and they have 23 ships. That is 6 months of guaranteed 5x higher than normal returns. See you after they report earning ….. I'm bullish and am all in and holding for profits in a couple months. All the newbs jumped ship already and panic sold into institution hands that will now make massive profits on this instead of of all the FOMO traders.

  13. Avataaar/Circle Created with python_avatars Jose M. says:

    New sub here.

  14. Avataaar/Circle Created with python_avatars Hustlas Story says:

    How do you find all of this info on why stocks raise or fall if you haven't traded it before? Id like to research but idk what is the best way to do so and who is a creditable source?

  15. Avataaar/Circle Created with python_avatars munoz20 says:

    Freshhh asss hair cut ricky

  16. Avataaar/Circle Created with python_avatars A1 BEASTMoDE says:

    Bad review, NAT will 🚀🚀🚀 may 18th

  17. Avataaar/Circle Created with python_avatars hen jer says:

    Oil prices will go back into negative territory by early June.

  18. Avataaar/Circle Created with python_avatars Cory says:

    From what the CEO said last week about making money etc., the most important info I retained was who they are carrying oil for and doing business with these days. I do like the lineup including shell Exxon etc. I was late to the party getting in at 6.4 and due to pdt rule I couldn’t sell when it ran up to 9. So patiently waiting for the next run up. Great vids Ricky I find them very informational for a beginning trader like myself. Thanks

  19. Avataaar/Circle Created with python_avatars Crewas Gaming says:

    Do you have a coupon for your course ? I’m want to start learning from you .

  20. Avataaar/Circle Created with python_avatars Speedytrip says:

    Don't forget the 9.30% dividend…Not a stock I would hold on to for years…but in the next 6-12 months, I think it has good potential.

  21. Avataaar/Circle Created with python_avatars Allama Sadi says:

    I think it will rally over $10 in May

  22. Avataaar/Circle Created with python_avatars Ian Gardiner says:

    I enjoy your helpful insights, Ricky. One unrelated question: what monitor do you use?

  23. Avataaar/Circle Created with python_avatars Casey Earl Dooley "Hillbilly" says:

    does it make sense that when oil demand increases. The first oil used will be the cheap storage with some spot. However won't this be inflation at it's finest. How long before true average demand for oil comes back. Once storage empties will prices t0 store crude rise at next refill? And will some hoard the cheap stored crude? There are a lot of variables at this point. I'm with Rick! I'ma watch n learn!

  24. Avataaar/Circle Created with python_avatars vasile popitan says:

    I notice many people that bought tanker stocks don’t know what they’re talking about. The stocks didn’t go up because of negative oil. They went up because of steep contango & traders chartering tankers to take advantage of that. This has been happening since March well before oil went negative. Also, oil didn’t go negative because of lack of storage. Oil went negative because speculators that never intended on taking delivery got caught and they paid for their mistake.

  25. Avataaar/Circle Created with python_avatars Dr. John Smith says:

    NAT >>..REAL REASON FOR PUMP IN DUMP REDDIT PENNYSTOCK GROUP,,,,,, THEY DID UVAS THE NEXT DAY AND MVIS AFTER THAT… PUMP AND DUMP (SEE CHARTS) SEE THERE THREAD

  26. Avataaar/Circle Created with python_avatars Dr. John Smith says:

    FORGET NAT READ THIS: FDA APPROVED YESTERDAY GOLD!!!!!! THANK ME LATER I LOST ON NAT.. HERE IS A REAL INVESTMENT

    VANCOUVER, Washington, May 04, 2020 (GLOBE
    NEWSWIRE) — CytoDyn
    Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a
    late-stage biotechnology company developing leronlimab (PRO 140), a CCR5
    antagonist with the potential for multiple therapeutic indications,
    today announced that the Company is expecting enrollment completion for
    its 75 patient, Phase 2 double blinded, placebo controlled, randomized
    study by the end of this month.

    CytoDyn has submitted a request to the FDA to grant expanded
    access, also known as “compassionate use,” to make leronlimab available
    for patients not eligible for participation in two ongoing clinical
    trials for coronavirus infections. Many severe and critically-ill
    patients, who have received off-label immunomodulatory treatments for
    COVID-19, are excluded from participation in the Company’s  Phase 2b/3
    clinical trial and could potentially benefit from access to leronlimab
    under a compassionate use program.

    There are 49 COVID-19 patients who have enrolled for treatment with
    leronlimab through eIND.  Four out of 11 critically ill patients with a
    multitude of pre-existing conditions survived after treatment, and of
    the next 38 patients, many were extubated, improved, or were discharged.

    Nader Pourhassan, Ph.D., President and Chief Executive Officer
    of CytoDyn said, “We
    are very excited about the continuing positive responses from eIND
    patients following their treatment with leronlimab. We are equally
    excited about the prospects for patients should the FDA grant access to
    leronlimab under the compassionate use program. During this past
    Saturday, we had to overcome many obstacles for two patients who
    desperately wanted leronlimab. One patient was in the same hospital that
    enrolled the first 11 patients and the second was a VIP patient in Los
    Angeles. Under the compassionate use program, we could avoid
    and quickly overcome this type of stress and turmoil which was very
    difficult for the patients, their families, the physicians, and CytoDyn.
     The daughter of a patient who was on a machine used for severe heart
    and lung failure contacted us directly and expressed her immense
    gratitude believing leronlimab saved her mother’s life. These are
    amazing times for us at CytoDyn;
    with the opportunity to wake up every day with the potential of saving
    somebody’s life. For sure, I could never have imagined such an
    incredible honor.”

    About Coronavirus Disease 2019
    CytoDyn
    is currently enrolling patients in two clinical trials for COVID-19, a
    Phase 2 randomized clinical trial for mild-to-moderate COVID-19
    population in the U.S.
    and a Phase 2b/3 randomized clinical trial for severe and critically ill
    COVID-19 population in several hospitals throughout the country.

    SARS-CoV-2 was identified as the cause of an outbreak of respiratory
    illness first detected in Wuhan,
    China. The origin of SARS-CoV-2 causing the COVID-19 disease
    is uncertain, and the virus is highly contagious. COVID-19 typically
    transmits person to person through respiratory droplets, commonly
    resulting from coughing, sneezing, and close personal contact.
    Coronaviruses are a large family of viruses, some causing illness in
    people and others that circulate among animals. For confirmed COVID-19
    infections, symptoms have included fever, cough, and shortness of
    breath. The symptoms of COVID-19 may appear in as few as two days or as
    long as 14 days after exposure. Clinical manifestations in patients have
    ranged from non-existent to severe and fatal. At this time, there are
    minimal treatment options for COVID-19.

    About Leronlimab (PRO 140) and BLA Submission for the HIV
    Combination Therapy
    The FDA has granted a “Fast Track”
    designation to CytoDyn
    for two potential indications of leronlimab for deadly diseases. The
    first as a combination therapy with HAART for HIV-infected patients and
    the second is for metastatic triple-negative breast cancer. Leronlimab
    is an investigational humanized IgG4 mAb that blocks CCR5, a cellular
    receptor that is important in HIV infection, tumor metastases, and other
    diseases, including NASH. Leronlimab has completed nine clinical trials
    in over 800 people, including meeting its primary endpoints in a pivotal
    Phase 3 trial (leronlimab in combination with standard antiretroviral
    therapies in HIV-infected treatment-experienced patients).

    In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it
    masks CCR5, thus protecting healthy T cells from viral infection by
    blocking the predominant HIV (R5) subtype from entering those cells.
    Leronlimab has been the subject of nine clinical trials, each of which
    demonstrated that leronlimab could significantly reduce or control HIV
    viral load in humans. The leronlimab antibody appears to be a powerful
    antiviral agent leading to potentially fewer side effects and less
    frequent dosing requirements compared with daily drug therapies
    currently in use. We would like to provide an update that the Biologics
    License Application (BLA) for Leronlimab as a Combination Therapy for
    Highly Treatment Experienced HIV Patients will be considered completed
    after the clinical datasets are submitted on May 11, 2020.
    The clinical datasets are updated to address FDA comments for mock
    datasets from March 12 and March 20, 2020.
    After the BLA submission is considered completed, FDA makes a filing
    decision and sets a PDUFA goal date. CytoDyn
    has Fast Track designation and a rolling review previously assigned by
    the FDA and plans to request a priority review for the BLA. A priority
    review designation means the FDA’s goal is to take action on the
    marketing application within six months of receipt (compared with 10
    months under standard review).

    In the setting of cancer, research has shown that CCR5 may play a role
    in tumor invasion, metastases, and tumor microenvironment control.
    Increased CCR5 expression is an indicator of disease status in several
    cancers. Published studies have shown that blocking CCR5 can reduce
    tumor metastases in laboratory and animal models of aggressive breast
    and prostate cancer. Leronlimab reduced human breast cancer metastasis
    by more than 98% in a murine xenograft model. CytoDyn
    is, therefore, conducting a Phase 1b/2 human clinical trial in
    metastatic triple-negative breast cancer and was granted Fast Track
    designation in May 2019. 

    The CCR5 receptor appears to play a central role in modulating immune
    cell trafficking to sites of inflammation. It may be crucial in the
    development of acute graft-versus-host disease (GvHD) and other
    inflammatory conditions. Clinical studies by others further support the
    concept that blocking CCR5 using a chemical inhibitor can reduce the
    clinical impact of acute GvHD without significantly affecting the
    engraftment of transplanted bone marrow stem cells. CytoDyn
    is currently conducting a Phase 2 clinical study with leronlimab to
    support further the concept that the CCR5 receptor on engrafted cells is
    critical for the development of acute GvHD, blocking the CCR5 receptor
    from recognizing specific immune signaling molecules is a viable
    approach to mitigating acute GvHD. The FDA has granted “orphan drug”
    designation to leronlimab for the prevention of GvHD.

  27. Avataaar/Circle Created with python_avatars ks kazi says:

    I have to invest your company sir I am from Bangladesh my telegram @shamik999

  28. Avataaar/Circle Created with python_avatars Nathan bond says:

    Because it was a pump and dump and the bald headed one on CNBC featured the head of the company on his television show and multiple YouTube channels were talking up the stock it was a classic pump-and-dump by the way it hit $9 for just mirror minutes you would have had to be incredibly lucky or a brilliant Trader to have sold at $9 the stock immediately started crashing hard and it's going to continue to crash back to its natural $2 price range it's been at for years

  29. Avataaar/Circle Created with python_avatars Connor Chang says:

    Just curious: do you have a big enough presence that you are able to notice a move in prices when you release a video?

  30. Avataaar/Circle Created with python_avatars Tj Lala says:

    There is a second wave coming and it will be more ruthless that would let in complete lockdown like dark age. NAT will rise again

  31. Avataaar/Circle Created with python_avatars personal hobbies says:

    Nat is a pump and dump lol 😆

  32. Avataaar/Circle Created with python_avatars Breezy8o8 says:

    98 percent of the video is . Oh don't trade something just because someone else's opinion or value aka rambling. 2 percent possible support at 4 to 5. This child is a joke with nice cars. Little TA. Little objective thinking . Little data or anything to fundamentally support any opinion. Just an excuse to make a video

  33. Avataaar/Circle Created with python_avatars Toronto Made says:

    Hey Ricky, Great video. People who have invested in NAT and don’t know about the company will panic and sell their shares due to the drop. The CEO of NAT stated himself that they’re making lots of money. That being said, I believe this stock is a short term hold. Their earnings is coming very soon however I believe there’s more downside before the stock spikes up

  34. Avataaar/Circle Created with python_avatars Ricky Gutierrez says:

    NAT had a temporary rally to $9 a share as oil went negative and rushed to find storage solutions, NAT became a temporary solution! Now that oil begins to experience an increase in demand and storage levels stabilize. It would then make sense on why NAT could pullback to previous lows. Let me know if you agree! Thank you for your time!

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.